Shots:

• Takeda acquires PvP Biologics following the P-I proof-of-mechanism study of TAK-062 (Kuma062) to treat uncontrolled celiac disease. Takeda exercises its option to acquire by paying ~$330M as development & regulatory milestone including $35M up front
• In 2017- the companies collaborated to develop novel therapies for celiac disease- under which Takeda got exclusive option to acquire PvP following receipt of a pre-defined development plan
• TAK-062 is designed to digest gluten before they exit the stomach- thus eliminating the symptoms and intestinal damage caused by celiac disease. Takeda is planning to initiate P-IIb study assessing TAK-062 in patients with the uncontrolled disease- maintaining a gluten-free diet

Click here ­to­ read full press release/ article | Ref: Takeda | Image: China Daily